Unusual Volume
FDA Rejects Summit Therapeutics Ivonescimab BLA, Citing Lack of Overall Survival Data
Read this in the Market Flux appSummit Therapeutics Inc. $SMMT
$11.81-16.50%as of publication
- 5D Change
- -33.99%
- Volume
- 37
- vs Average
- 18.5×
- Market Cap
- $11.29B
The U.S. Food and Drug Administration issued a Complete Response Letter on November 15, 2026, refusing to approve Summit Therapeutics' Biologics License Application for ivonescimab in combination with platinum-containing chemotherapy. The drug was under review for the treatment of locally advanced or metastatic non-small cell lung cancer in patients who had previously received EGFR tyrosine kinase inhibitor therapy. The FDA concluded that substantial evidence of effectiveness had not been established, finding that progression-free survival gains demonstrated in the HARMONi study were insufficient to support a positive benefit-risk profile without a statistically significant improvement in overall survival.
The rejection sent Summit shares to a 52-week low of $12.04, with the stock down roughly 12 to 20 percent in premarket trading on Monday, November 16. Akeso, the Hong Kong-listed biotech that developed ivonescimab and holds rights in China while Summit holds exclusive commercialization rights outside China, saw its shares fall as much as 31.8% in Hong Kong. The FDA's demand for overall survival data represents a significant reset for one of the most closely watched oncology programs in biotech, and Summit will need to either generate that data from an ongoing or new trial or propose an alternative path to the agency.
© AI-generated summary is provided by Market Flux
Sources
- PiQMarketsAkeso shares fall 31.8% after FDA rejects ivonescimab application Shares in Hong Kong-listed Akeso fell as much as 31.8% on Monday, November 16, 2026, after the US Food and Drug Administration rejected its cancer drug application. Summit Therapeutics, which holds exclusive rights to develop and commercialize ivonescimab outside China, said the FDA found the drug did not establish substantial evidence of effectiveness.
- InvestingWhy is Summit Therapeutics stock plunging today?
- BioStocks$SMMT ↓ 20% PM FDA issued CRL for Ivonescimab BLA
- NasdaqSummit Therapeutics Inc. Receives FDA Complete Response Letter on November 15, 2026
- BenzingaSummit Therapeutics Faces FDA Hurdle For Lead Lung Cancer Drug, Stock Tumbles
- BriefingcomGapping up: $LXEO +46.6% $OCS +12.9% $DRTS +10.6% $IDYA +6.6% $ZYME +3.7% Gapping down: $HELP -26.8% $SMMT -13.8% $POET -8.7% $WULF -5.2%
- MarketwatchThe FDA declined to approve one of biotech’s most closely watched cancer drugs
- Market WatchThe FDA declined to approve one of biotech's most closely watched cancer drugs
Show 8 more
- ZerohedgePremarket movers Mag 7 stocks are mostly lower (Nvidia (NVDA) -3%, Microsoft (MSFT) +0.05%, Apple (AAPL) +0.4%, Alphabet (GOOGL) -0.5%, Amazon (AMZN) -0.6%, Tesla (TSLA) -1.1%, Meta Platforms (META) -0.7%) Semiconductor stocks slip as investors prepare for a raft of risk events this week, including Nvidia’s earnings, Anthropic’s IPO and a meeting between the leaders of the US, China and Russia. Movers include Broadcom (AVGO) -3%, Intel (INTC) -5% Cryptocurrency-exposed stocks slide after Bitcoin extends a recent plunge to fall below $65,000. Managed-care companies rise after the Trump administration let states delay a requirement that some people in the Medicaid program work, volunteer or go to school to get health insurance. Centene (CNC) +3%, Molina (MOH) +2% Alpha Tau Medical (DRTS) climbs 11% after the drug developer gave interim results from a trial of its investigative treatment for brain cancer. Aramark (ARMK) falls 5% after the food and related products distributor reported adjusted earnings per share and revenue for the fourth quarter that missed the consensus estimates. 2027 guidance includes a slight miss on EPS growth. The midpoint of the organic revenue growth projection is also below the Street estimate. Blackstone Digital Infrastructure Trust (BXDC) climbs 5% after signing an agreement to buy a 75% majority interest, worth about $5 billion, in two data center joint ventures with Amazon Web Services. Diamondback Energy (FANG) slips 1% after agreeing to buy certain subsidiaries of closely held oil driller Double Eagle for $2.15 billion in cash and 15.56 million shares, growing its position as one of the largest operators in the world’s most productive shale patch. Eli Lilly & Co. (LLY) inches about 1% higher after agreeing to buy Calytrix Bio, Inc. in a deal that could be worth up to $1.5 billion in the latest transaction by the acquisitive US drug company. Summit Therapeutics (SMMT) falls 12% after US regulators rejected the lung cancer treatment that the company and partner Akeso Inc. are developing. Take-Two Interactive (TTWO) is up 2% as Jefferies touts strong pre-orders ahead of the Grand Theft Auto VI game launch on Thursday. Telus (TU) soars 28% after Quebecor submitted a proposal to buy the company.
- OpenOutcrier$SMMT (-14.3% pre) Summit Therapeutics Faces FDA Hurdle For Lead Lung Cancer Drug, Stock Tumbles
- BarronsSummit's FDA Setback Is a Reality Check for Next-Gen Cancer Drugs
- BarronsonlineSummit Therapeutics stock sinks as regulators decline to approve ivonescimab, a next-generation cancer therapy backed by AstraZeneca.
- TheflynewsMorning Movers: Blackstone Digital jumps after acquiring AWS data centers $DRTS $BXDC $LLY $STGW $ARMK $FANG $SMMT $YETI $LHX
- JonnajarianRebel’s Edge 🏴☠️ 1pm Line up: #VIX $TU $SNDK $CGON $SMMT 🏈 NAJARIAN SPORTS 🏴☠️ with @petenajarian Parity is here in college football with only two undefeated teams left, is it the craziest year ever? Are the 49ers and Jacksonville the best of the NFC and AFC? #ITSNOTANOPTION 📙
- MarketRebelsSTARTS NOW! Rebel’s Edge 🏴☠️ 1pm Line up: #VIX $TU $SNDK $CGON $SMMT 🏈 NAJARIAN SPORTS 🏴☠️ with @petenajarian Parity is here in college football with only two undefeated teams left, is it the craziest year ever? Are the 49ers and Jacksonville the best of the NFC and AFC? #ITSNOTANOPTION 📙
- Schaeffers Research2 Cancer-Drug Developers Seeing Unusual Options Volume